{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T20:09:01Z","timestamp":1769976541588,"version":"3.49.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ccm.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T16:25:30Z","timestamp":1693844730000},"page":"91-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neurosarcoidosis and Neurologic Complications of Sarcoidosis Treatment"],"prefix":"10.1016","volume":"45","author":[{"given":"Mareye","family":"Voortman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Drent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barney J.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ccm.2023.08.005_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement_6","key":"10.1016\/j.ccm.2023.08.005_bib2","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1513\/AnnalsATS.201707-566OT","article-title":"High-risk sarcoidosis. Current Concepts and research Imperatives","volume":"14","author":"Sauer","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0895-4356(93)90150-Y","article-title":"The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis","volume":"46","author":"Takada","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.rdc.2017.06.008","article-title":"Neurosarcoidosis","volume":"43","author":"Ungprasert","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/14737175.2015.1037288","article-title":"Neurosarcoidosis: diagnosis, therapy and biomarkers","volume":"15","author":"Bagnato","year":"2015","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib7","first-page":"373","article-title":"Isolated neurosarcoidosis: case series in 2 sarcoidosis centers","volume":"18","author":"Nozaki","year":"2012","journal-title":"Neurol"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.005_bib8","first-page":"1906","article-title":"Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results","volume":"265","author":"Kidd","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.005_bib9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.ccm.2023.08.005_bib10","doi-asserted-by":"crossref","first-page":"e3277","DOI":"10.1097\/MD.0000000000003277","article-title":"Neurosarcoidosis in a tertiary Referral center: a Cross-Sectional cohort study","volume":"95","author":"Leonhard","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib11","first-page":"292","article-title":"Clinical manifestations of neurosarcoidosis in The Netherlands","volume":"10","author":"Voortman MF","year":"2019","journal-title":"J\u00a0Neurol Neurosci"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2009.09.012","article-title":"Neurologic presentations of sarcoidosis","volume":"28","author":"Stern","year":"2010","journal-title":"Neurol Clin"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/ene.15295","article-title":"Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: a retrospective cohort study and review of the literature","volume":"29","author":"Nolte","year":"2022","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000743","article-title":"Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system","volume":"7","author":"Lord","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.005_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2213-2600(21)00311-8","article-title":"Misconceptions regarding symptoms of sarcoidosis","volume":"9","author":"Drent","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib16","first-page":"2","article-title":"Everyday cognitive failure in patients suffering from neurosarcoidosis","volume":"36","author":"Voortman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.005_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14737175.2022.2108705","article-title":"Neurosarcoidosis: an update on diagnosis and therapy","volume":"22","author":"Ungprasert","year":"2022","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MAO.0000000000000501","article-title":"Cranial base manifestations of neurosarcoidosis: a review of 305 patients","volume":"36","author":"Carlson","year":"2015","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.ccm.2023.08.005_bib19","first-page":"16","article-title":"Granulomatous and nongranulomatous neurological sarcoidosis","author":"Tavee","year":"2022","journal-title":"Eur Respir Monogr"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib20","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200028","article-title":"Pachymeningitis in biopsy-Proven sarcoidosis: clinical course, Radiographic findings, response to treatment, and long-term outcomes","volume":"9","author":"Chakales","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0037-1604165","article-title":"Neurosarcoidosis","volume":"38","author":"Culver","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MCP.0000000000000401","article-title":"Many faces of neurosarcoidosis: from chronic meningitis to myelopathy","volume":"23","author":"Fritz","year":"2017","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib23","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib24","first-page":"25","article-title":"Neurosarcoidosis in a public safety net hospital: a study of 82 cases","volume":"36","author":"Dorman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib25","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001063","article-title":"Vascular involvement in neurosarcoidosis: early experiences from intracranial vessel Wall imaging","volume":"8","author":"Bathla","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.005_bib26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/qjmed\/hcs121","article-title":"Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients","volume":"105","author":"Langrand","year":"2012","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.005_bib27","first-page":"e2362","article-title":"Stroke presenting as a complication of sarcoidosis in an otherwise asymptomatic patient","volume":"10","author":"Memon","year":"2018","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.005_bib28","first-page":"2333","article-title":"Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis","volume":"265","author":"Jachiet","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.12.003","article-title":"Sarcoidosis presenting as transient ischemic attack status","volume":"21","author":"Gonzalez-Aramburu","year":"2012","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1941874416656730","article-title":"Neurosarcoidosis presenting with Recurrent strokes: a case report and literature review","volume":"7","author":"Raza","year":"2017","journal-title":"Neurohospitalist"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.005_bib31","first-page":"4783","article-title":"Spinal cord sarcoidosis in Japan: utility of cerebrospinal fluid examination and nerve conduction study for diagnosis and prognosis prediction","volume":"269","author":"Fujisawa","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000722","article-title":"Clinical and MRI phenotypes of sarcoidosis-associated myelopathy","volume":"7","author":"Murphy","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib33","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001170","article-title":"Neurosarcoidosis of the cauda equina: clinical course, Radiographic and electrodiagnostic findings, response to treatment, and outcomes","volume":"9","author":"Bou","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MD.0b013e3181d5c6b4","article-title":"Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study","volume":"89","author":"Cohen-Aubart","year":"2010","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib35","first-page":"981","article-title":"Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients","volume":"263","author":"Durel","year":"2016","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ccm.2023.08.005_bib36","doi-asserted-by":"crossref","first-page":"577864","DOI":"10.1016\/j.jneuroim.2022.577864","article-title":"Peripheral neuropathy in sarcoidosis","volume":"368","author":"Tavee","year":"2022","journal-title":"J\u00a0Neuroimmunol"},{"issue":"Pt 2","key":"10.1016\/j.ccm.2023.08.005_bib37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/brain\/awf027","article-title":"Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients","volume":"125","author":"Said","year":"2002","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.005_bib38","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1212\/WNL.41.10.1558","article-title":"Sarcoid peripheral neuropathy","volume":"41","author":"Zuniga","year":"1991","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1941874419865640","article-title":"An Atypical and multifactorial acute immune polyradiculopathy: a case report","volume":"10","author":"Brier","year":"2020","journal-title":"Neurohospitalist"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CND.0b013e3181ae3be9","article-title":"Neurosarcoidosis presenting as Guillain-Barre-like syndrome. A case report and review of the literature","volume":"11","author":"Fahoum","year":"2009","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.005_bib41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2169\/internalmedicine.52.7788","article-title":"Multifocal conduction block in a patient with sarcoid neuropathy: successful treatment with intravenous immunoglobulin","volume":"52","author":"Kono","year":"2013","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib42","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.24652","article-title":"Sarcoid polyneuropathy masquerading as chronic inflammatory demyelinating polyneuropathy","volume":"52","author":"Singhal","year":"2015","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.005_bib43","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American thoracic Society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.005_bib44","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and Consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium Consensus group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis--diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.ccm.2023.08.005_bib46","doi-asserted-by":"crossref","first-page":"577871","DOI":"10.1016\/j.jneuroim.2022.577871","article-title":"Clinical features and diagnosis of neurosarcoidosis - review article","volume":"368","author":"Barreras","year":"2022","journal-title":"J\u00a0Neuroimmunol"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.005_bib47","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1373\/49.9.1510","article-title":"Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis","volume":"49","author":"Rothkrantz-Kos","year":"2003","journal-title":"Clin Chem"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.005_bib48","first-page":"1855","article-title":"Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis","volume":"257","author":"Petereit","year":"2010","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ccm.2023.08.005_bib49","doi-asserted-by":"crossref","first-page":"105855","DOI":"10.1016\/j.rmed.2019.105855","article-title":"Evaluating S100B as a serum biomarker for central neurosarcoidosis","volume":"162","author":"Moss","year":"2020","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/18756190MTA44NjEs3","article-title":"Targeting S100B protein as a Surrogate biomarker and its role in various neurological disorders","volume":"19","author":"Langeh","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200905-0696OC","article-title":"Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2","volume":"181","author":"Chen","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.005_bib52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcp042","article-title":"Presentations and outcomes of neurosarcoidosis: a study of 54 cases","volume":"102","author":"Pawate","year":"2009","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib53","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1038\/s41598-021-92967-6","article-title":"Clinical characterization and outcomes of 85 patients with neurosarcoidosis","volume":"11","author":"Ramos-Casals","year":"2021","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10.1016\/j.ccm.2023.08.005_bib54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2013.09.008","article-title":"Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity","volume":"335","author":"Wengert","year":"2013","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ccm.2023.08.005_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.05.020","article-title":"Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis","volume":"285","author":"Bridel","year":"2015","journal-title":"J\u00a0Neuroimmunol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib56","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000725","article-title":"Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis","volume":"7","author":"Otto","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.005_bib57","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/ene.13975","article-title":"The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study","volume":"26","author":"Chazal","year":"2019","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2214\/ajr.182.2.1820289","article-title":"Imaging manifestations of neurosarcoidosis","volume":"182","author":"Smith","year":"2004","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib59","first-page":"655","article-title":"MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment","volume":"20","author":"Christoforidis","year":"1999","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6 Pt 2","key":"10.1016\/j.ccm.2023.08.005_bib60","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.lpm.2011.12.017","article-title":"Neurosarcoidosis: clinical manifestations, diagnosis and treatment","volume":"41","author":"Nozaki","year":"2012","journal-title":"Presse Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1971400918806634","article-title":"Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature","volume":"32","author":"Soni","year":"2019","journal-title":"NeuroRadiol J"},{"issue":"14","key":"10.1016\/j.ccm.2023.08.005_bib62","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000200020","article-title":"Prognostic factors and treatment efficacy in spinal cord sarcoidosis: an observational cohort with long-term Follow-up","volume":"98","author":"Gavoille","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib63","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.mayocp.2020.01.032","article-title":"Whole-body 18F-FDG PET-CT in the diagnosis of neurosarcoidosis","volume":"95","author":"Fritz","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13550-020-00742-x","article-title":"FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET","volume":"10","author":"Martineau","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.ccm.2023.08.005_bib65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/B978-0-444-52902-2.00027-8","article-title":"Sarcoidosis of the peripheral nervous system","volume":"115","author":"Said","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"24","key":"10.1016\/j.ccm.2023.08.005_bib66","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib67","first-page":"891","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"20","key":"10.1016\/j.ccm.2023.08.005_bib68","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.wnl.0000341278.26993.22","article-title":"Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil","volume":"72","author":"Moravan","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib70","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.rmed.2008.08.016","article-title":"Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis","volume":"103","author":"Sodhi","year":"2009","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.005_bib71","first-page":"2466","article-title":"Effects of immunotherapies and clinical outcomes in neurosarcoidosis: a retrospective cohort study","volume":"268","author":"Arun","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ccm.2023.08.005_bib72","doi-asserted-by":"crossref","first-page":"105811","DOI":"10.1016\/j.clineuro.2020.105811","article-title":"Sarcoidosis of the central nervous system: safety and efficacy of treatment, and experience of biological therapies","volume":"194","author":"Kidd","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jocn.2005.08.021","article-title":"Leflunomide-induced peripheral neuropathy","volume":"14","author":"Kho","year":"2007","journal-title":"J\u00a0Clin Neurosci"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib74","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib76","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1445-5994.2011.02457.x","article-title":"Medically refractory neurosarcoidosis treated with infliximab","volume":"41","author":"Pereira","year":"2011","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.005_bib77","first-page":"2064","article-title":"Adalimumab for CNS sarcoidosis: single-center experience and literature review","volume":"269","author":"Hutto","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib78","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ccm.2023.08.005_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418805732","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","volume":"11","author":"Zella","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib80","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1212\/WNL.0b013e3181ec7ff9","article-title":"A\u00a0case of neurosarcoidosis successfully treated with rituximab","volume":"75","author":"Bomprezzi","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.005_bib81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.ccm.2023.08.005_bib82","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","author":"Sharp","year":"2019","journal-title":"Respir Med X"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.005_bib83","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib84","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCP.0000000000000889","article-title":"Drug-induced comorbidities in patients with sarcoidosis","volume":"28","author":"Drent","year":"2022","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.005_bib85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.005_bib86","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating events following initiation of anti-TNFalpha therapy in the British Society for Rheumatology Biologics Registry in rheumatoid arthritis","volume":"8","author":"Taylor","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.005_bib87","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000501","article-title":"Nutrition and corticosteroids in the treatment of sarcoidosis","volume":"24","author":"Bast","year":"2018","journal-title":"Curr Opin Pulm Med"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:18:34Z","timestamp":1759454314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523123000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0272523123000746"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2023.08.005","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurosarcoidosis and Neurologic Complications of Sarcoidosis Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}